Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Editas MedicineEDIT -2.24%51 Cash Ratio is 3.11 as of Mar. 2026, which is 57% below its 10-year median of 7.31. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.74 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,382 Biotechnology companies, Editas Medicine ranks better than 51.52% on this metric.
Editas Medicine has a Cash Ratio of 3.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Editas Medicine's Cash Ratio or its related term are showing as below:
EDIT'
s Cash Ratio Range Over the Past 10 Years
Min: 2.68 Med: 7.31 Max: 15.86
Current: 3.11
During the past 13 years, Editas Medicine's highest Cash Ratio was 15.86. The lowest was 2.68. And the median was 7.31.
EDIT's Cash Ratio is ranked better than 51.52% of 1382
companies
in the Biotechnology industry
Industry Median: 2.94
vs EDIT: 3.11
Editas Medicine (NAS:EDIT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Editas Medicine Cash Ratio Related Terms
Editas Medicine Cash Ratio Historical Data
* Premium members only.
The historical data trend for Editas Medicine's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Editas Medicine's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (EDIT) has a Cash Ratio of 3.11 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Editas Medicine and its competitors. This is 57% below median its historical median of 7.31. Over the past decade, Editas Medicine's Cash Ratio has ranged from 2.68 to 15.86. According to the industry distribution chart, Editas Medicine ranks #670 out of 1382 companies in the Biotechnology industry, placing it in the top 48.5%.
Is Editas Medicine's Cash Ratio too high?
Editas Medicine's current Cash Ratio of 3.11 is 57% below median its 10-year median of 7.31. Over the past 10 years, this metric has ranged from a low of 2.68 to a high of 15.86. The Biotechnology industry median Cash Ratio is 2.94. Editas Medicine's value of 3.11 is 5.8% above this industry median. Based on the distribution chart, Editas Medicine ranks #670 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Cash Ratio compare to BNTC and PBYI?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #670 out of 1382 companies for Cash Ratio. This puts Editas Medicine in the upper half of its industry. The industry median Cash Ratio is 2.94. Editas Medicine's value of 3.11 is 5.8% above this benchmark. Historically, Editas Medicine's own Cash Ratio has ranged from 2.68 to 15.86 over the past decade. While the company's 10-year median is 7.31 vs. the industry median of 2.94, Editas Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Editas Medicine's current Cash Ratio of 3.11 is 5.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Editas Medicine and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Editas Medicine's current Cash Ratio is 3.11, which is 57% below median its own 10-year median of 7.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.74, compared to a current price of $2.62 — trading 50.6% above its estimated fair value. The current Cash Ratio is 3.11, which is 57% below median its 10-year median of 7.31 and 5.8% above the Biotechnology industry median of 2.94. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Cash Ratio is 3.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $2.62 is trading 50.6% above its estimated GF Value™ of $1.74.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
Cash Ratio: 3.11 (57% below median its 10-year median of 7.31)
GF Value™: $1.74 vs. price of $2.62 (50.6% above fair value)
Industry Position: 5.8% above the Biotechnology median (#670 of 1382)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score
Get the complete analysis for EDIT
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
